Johnson & Johnson - U.S. FDA Approves EDURANT PED for Certain Pediatric Patients Living with HIV-1

Published: 2024-03-20 08:02:26 ET JNJ

Titusville - Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved EDURANT PED (rilpivirine) for the treatment of HIV-1 in combination with other antiretroviral therapies (ARVs) in treatment-naive children (with HIV-1 RNA

(C) 2024 Electronic News Publishing, source ENP Newswire